{"id":842917,"date":"2025-04-28T17:00:50","date_gmt":"2025-04-28T21:00:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/universal-health-services-inc-announces-2025-first-quarter-financial-results\/"},"modified":"2025-04-28T17:00:50","modified_gmt":"2025-04-28T21:00:50","slug":"universal-health-services-inc-announces-2025-first-quarter-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/universal-health-services-inc-announces-2025-first-quarter-financial-results\/","title":{"rendered":"UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2025 FIRST QUARTER FINANCIAL RESULTS"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n Consolidated Results of Operations, As Reported and As Adjusted\u00a0 \u2013 Three-month periods ended March 31, 2025<\/span> and 2024:<\/u>
\n <\/i>\n <\/p>\n

\n
\n KING OF PRUSSIA, Pa.<\/span>
\n <\/span>, April 28, 2025<\/span><\/span> \/PRNewswire\/ — Universal Health Services, Inc. (NYSE:\u00a0UHS) announced today that its reported net income attributable to UHS was $316.7 million<\/span>, or $4.80<\/span> per diluted share, during the first quarter of 2025, as compared to $261.8 million<\/span>, or $3.82<\/span> per diluted share, during the first quarter of 2024. Net revenues increased by 6.7% to $4.100 billion<\/span> during the first quarter of 2025, as compared to $3.844 billion<\/span> during the first quarter of 2024.<\/p>\n

As reflected on the Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”), our adjusted net income attributable to\u00a0UHS during the first quarter of 2025 was $319.5 million<\/span>, or $4.84<\/span> per diluted share, as compared to $253.1 million<\/span>, or $3.70<\/span> per diluted share, during the first quarter of 2024.<\/p>\n

As reflected on the Supplemental Schedule, included in our reported results during the first quarter of 2025 were: (i) an unrealized after-tax loss of $3.3 million<\/span>, or $.05<\/span> per diluted share ($4.3 million<\/span> pre-tax), resulting from a decrease in the market value of certain equity securities (included in “Other (income) expense, net”), and; (ii) a favorable net after-tax impact of $0.5 million<\/span>, or $.01<\/span> per diluted share, resulting from the net tax benefit recorded in connection with “ASU 2016-09”, Compensation \u2013 Stock Compensation: Improvements to Employee Share-Based Payment Accounting, net of the impact of executive compensation limitations pursuant to IRC section 162(m).<\/p>\n

As reflected on the Supplemental Schedule, included in our reported results during the first quarter of 2024 were: (i) a favorable after-tax impact of $9.2 million<\/span>, or $.13<\/span> per diluted share, resulting from the tax benefit recorded in connection with employee share-based payments pursuant to\u00a0ASU 2016-09, and; (ii) an unrealized after-tax loss of $0.4 million<\/span>, or $.01<\/span> per diluted share ($0.6 million<\/span> pre-tax), resulting from a decrease in the market value of certain equity securities.<\/p>\n

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”, NCI is net income attributable to noncontrolling interests), was $603.9 million<\/span> during the first quarter of 2025, as compared to $525.9 million<\/span> during the first quarter of 2024. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, was $598.2 million<\/span> during the first quarter of 2025, as compared to $525.8 million<\/span> during the first quarter of 2024.<\/p>\n

\n
\n Acute Care Services \u2013 Three-month periods ended March 31, 2025<\/span> and 2024:<\/u>
\n <\/i>\n <\/p>\n

During the first quarter of 2025, at our acute care hospitals owned during both periods (“same facility basis”), adjusted admissions (adjusted for outpatient activity) increased by 2.4% while adjusted patient days increased by 0.3%, as compared to the first quarter of 2024. At these facilities, during the first quarter of 2025, net revenue per adjusted admission increased by 2.5% while net revenue per adjusted patient day increased by 4.7%, as compared to the first quarter of 2024. Net revenues generated from our acute care services, on a same facility basis, increased by 6.5% during the first quarter of 2025, as compared to the first quarter of 2024.<\/p>\n

\n
\n Behavioral Health Care Services \u2013 Three-month periods ended March 31, 2025<\/span> and 2024:<\/u>
\n <\/i>\n <\/p>\n

During the first quarter of 2025, at our behavioral health care facilities on a same facility basis, adjusted admissions decreased by 1.6% while adjusted patient days decreased by 0.3%, as compared to the first quarter of 2024. At these facilities, during the first quarter of 2025, net revenue per adjusted admission increased by 7.2% and net revenue per adjusted patient day increased by 5.8%, as compared to the first quarter of 2024. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 5.5% during the first quarter of 2025, as compared to the first quarter of 2024.<\/p>\n

\n
\n Net Cash Provided by Operating Activities and Liquidity:<\/u>
\n <\/i>\n <\/p>\n

\n Net Cash Provided by Operating Activities:<\/i>\n <\/p>\n

During the three-month period ended March 31, 2025<\/span>, our net cash provided by operating activities was $360 million<\/span> as compared to $396 million<\/span> during the first quarter of 2024. The $36 million<\/span> net decrease in our net cash provided by operating activities consisted of: (i) a favorable change of $69 million<\/span> resulting from an increase in net income plus\/minus depreciation and amortization expense, stock-based compensation expense and gains on sales of assets and businesses; (ii) an unfavorable change of $144 million<\/span> in accounts receivable due, in part, to delays in receipt of funds in connection with certain Medicaid supplement payment programs in various states (approximately $82 million<\/span> of which related to the Nevada<\/span> state directed payment program which was approved by the Centers for Medicare and Medicaid Services in April, 2025, retroactive to January 1, 2025<\/span>); (iii) a favorable change of $20 million<\/span> in other assets and deferred charges; (iv) a favorable change of $16 million<\/span> in accrued and deferred income taxes, and; (v) $3 million<\/span> of other combined net favorable changes.\u00a0 \u00a0\u00a0\u00a0<\/p>\n

\n Liquidity:<\/i>\n <\/p>\n

As of March 31, 2025<\/span>, we had $1.02 billion<\/span> of aggregate available borrowing capacity pursuant to our $1.3 billion<\/span> revolving credit facility, net of outstanding borrowings and letters of credit.\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0<\/p>\n

\n
\n Stock Repurchase Program:<\/u>
\n <\/i>\n <\/p>\n

In connection with our stock repurchase program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions.\u00a0<\/p>\n

Pursuant to this program, during the first quarter of 2025, we have repurchased approximately 1.0 million shares at an aggregate cost of approximately $180.6 million<\/span> (average price of approximately $181<\/span> per share).<\/p>\n

As of March 31, 2025<\/span>, we had an aggregate available repurchase authorization of approximately $643.7 million<\/span> pursuant to our stock repurchase program.<\/p>\n

\n
\n Conference call information:<\/u>
\n <\/i>\n <\/p>\n

We will hold a conference call for investors and analysts at 9:00 a.m. eastern time<\/span> on April 29, 2025<\/span>. A live webcast of the call will be available on our website at\u00a0www.uhs.com<\/a>. To participate via telephone, please register in advance at this link<\/a>. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call.<\/p>\n

\n
\n General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:<\/u>
\n <\/i>\n <\/p>\n

One of the nation’s largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. (the “Company”) has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2024 were $15.8 billion<\/span>. UHS ranked #299 on the Fortune 500; and #399 on Forbes’<\/i> list of America’s Largest Public Companies. In 2025, UHS was again recognized as one of the World’s Most Admired Companies by Fortune<\/i>. \u00a0<\/p>\n

Our operating philosophy is as effective today as it was upon the Company’s founding in 1979, enabling us to provide compassionate care to our patients and their loved ones.\u00a0 Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.<\/p>\n

Headquartered in King of Prussia, PA<\/span>, UHS has approximately 99,300 employees and, through its subsidiaries, operates 29 inpatient acute care hospitals, 334 inpatient behavioral health facilities, 60 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 states, Washington, D.C.<\/span>, the United Kingdom<\/span> and Puerto Rico<\/span>. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT).\u00a0 For additional information visit www.uhs.com<\/a>.<\/p>\n

This press release contains forward-looking statements based on current management expectations.\u00a0 Numerous factors, including those disclosed herein, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A<\/i>–Risk Factors,<\/i> and Item 7-Forward-Looking Statements and Risk Factors,<\/i> in our Form 10-K for the year ended December 31, 2024<\/span>), may cause the results to differ materially from those anticipated in the forward-looking statements.\u00a0 These statements are subject to risks and uncertainties and therefore actual results may differ materially.\u00a0 Readers should not place undue reliance on such forward-looking statements which reflect management’s view only as of the date hereof.\u00a0 We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.\u00a0<\/p>\n

Many of the factors that could affect our future results are beyond our control or ability to predict, including, but not limited to:\u00a0\u00a0<\/p>\n